ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "a1d546cd-7791-4f49-890c-3cc7ae6977b1"}, "_deposit": {"id": "14723", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "14723"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00014723", "sets": ["456", "1071"]}, "item_7_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "Phase I Dose Escalation Study of Multicyclic, Dose-Intensive Chemotherapy with Peripheral Blood Stem Cell Support for Small Cell Lung Cancer"}]}, "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2001-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "9", "bibliographicPageEnd": "437", "bibliographicPageStart": "432", "bibliographicVolumeNumber": "115", "bibliographic_titles": [{"bibliographic_title": "新潟医学会雑誌"}, {"bibliographic_title": "新潟医学会雑誌", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "A phase I dose-escalation study of multicyclic, ifosfamide, carboplatin, and etoposide (ICE) with sequential reinfusion of peripheral blood stem-cells (PBSCs) was conducted to determine the maximum-tolerated dose (MTD) of ICE. Twenty-seven patients with SCLC (LD : 9, ED : 18) were treated with ifosfamide (3000-9000mg/m^2, 24-hour-infusion), carboplatin (300-400mg/m^2), and etoposide (300mg/m^2) followed by subcutaneous injection of filgrastim (75μg/day) through day 4 to the day of PBSC collection. PBSC were harvested when the WBC count reached ≧5×10^9/L. The leukapheresis product was cryopreserved and reinfused on day 4 of the next cycle, which was started 48 hours after the last PBSC collection. The ifosfamide dose was escalated as follows : 3000mg/m^2 (level 1), 5000mg/m^2 (level 2), 7000mg/m^2 (level 3), 9000mg/m^2 (level 4). Patients with LD were treated with concurrent radiotherapy at 1.5 Gy twice daily for the initial 3 weeks to a total dose of 45Gy and MTD, defined separately. Patients were evaluated for hematologic and non-hematologic toxicity, actual dose intensities, as well as response to the therapy. The maximum-tolerated dose (MTD) was defined as the dose level at which the level produced more than 5 days of grade 4 myelosuppression or non-hematologic toxicity greater than grade 3 in two thirds of the patients. For ED cases, MTD was level 4 and the recommended dose of ifosfamide was 7000mg/m^2. For LD cases, the recommended dose of ifosfamide was 5000mg/m^2. The dose limiting toxicity of multicyclic ICE was hematologic toxicity and CNS toxicity which manifested as ataxia. Tumor responses were seen in all patients, with 14 patients showing a complete response. The actual total dose-intensity at the recommended dose level was 2.2 and 1.74, for ED and LD, respectively, compared with previously reported ICE regimens. PBSC support for dose-intensive ICE regimen permitted dose escalation of ifosfamide with a mean interval of 16-17 days. We conclude this regimen is well tolerated, with acceptable hematological and non-hematological toxicity.", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "94977", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Yoshizawa, Hirohisa"}]}, {"nameIdentifiers": [{"nameIdentifier": "94978", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Matsumoto, Naoya"}]}, {"nameIdentifiers": [{"nameIdentifier": "94979", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Mochizuki, Hiroshi"}]}, {"nameIdentifiers": [{"nameIdentifier": "94980", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Kuriyama, Hideyuki"}]}, {"nameIdentifiers": [{"nameIdentifier": "94981", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Kagamu, Hiroshi"}]}, {"nameIdentifiers": [{"nameIdentifier": "94982", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Suzuki, Eiichi"}]}, {"nameIdentifiers": [{"nameIdentifier": "94983", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Gejyo, Fumitake"}]}]}, "item_7_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "新潟医学会"}]}, "item_7_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "吉澤, 弘久"}], "nameIdentifiers": [{"nameIdentifier": "94970", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "松本, 尚也"}], "nameIdentifiers": [{"nameIdentifier": "94971", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "望月, 博史"}], "nameIdentifiers": [{"nameIdentifier": "94972", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "栗山, 英之"}], "nameIdentifiers": [{"nameIdentifier": "94973", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "各務, 博"}], "nameIdentifiers": [{"nameIdentifier": "94974", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "鈴木, 栄一"}], "nameIdentifiers": [{"nameIdentifier": "94975", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "下条, 文武"}], "nameIdentifiers": [{"nameIdentifier": "94976", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-07"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "115(9)_432-437.pdf", "filesize": [{"value": "1.4 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1400000.0, "url": {"label": "115(9)_432-437.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/14723/files/115(9)_432-437.pdf"}, "version_id": "800a2eeb-27ec-4133-a576-034f245cb1b1"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Small cell lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Dose intensive chemotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Granulocyte Colony-Stimulating Factor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Hematopoietic Stem Cell Transplantation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Leukapheresis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "小細胞肺癌", "subitem_subject_scheme": "Other"}, {"subitem_subject": "高用量化学療法", "subitem_subject_scheme": "Other"}, {"subitem_subject": "顆粒球コロニー刺激因子", "subitem_subject_scheme": "Other"}, {"subitem_subject": "造血幹細胞移植", "subitem_subject_scheme": "Other"}, {"subitem_subject": "幹細胞採取", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "2)小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会)", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "2)小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会)"}, {"subitem_title": "2)小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会)", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["456", "1071"], "permalink_uri": "http://hdl.handle.net/10191/48382", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-11-09"}, "publish_date": "2017-11-09", "publish_status": "0", "recid": "14723", "relation": {}, "relation_version_is_last": true, "title": ["2)小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会)"], "weko_shared_id": null}
  1. 0 資料タイプ別
  2. 03 紀要論文
  1. 250 大学院医歯学総合研究科(医)
  2. 20 紀要
  3. 02 新潟医学会雑誌
  4. 第115巻第9号

2)小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会)

http://hdl.handle.net/10191/48382
http://hdl.handle.net/10191/48382
1621ca79-105e-49ee-9231-02ecc9928795
名前 / ファイル ライセンス アクション
115(9)_432-437.pdf 115(9)_432-437.pdf (1.4 MB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2017-11-09
タイトル
タイトル 2)小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会)
タイトル
言語 en
タイトル 2)小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会)
言語
言語 jpn
キーワード
主題Scheme Other
主題 Small cell lung cancer
キーワード
主題Scheme Other
主題 Dose intensive chemotherapy
キーワード
主題Scheme Other
主題 Granulocyte Colony-Stimulating Factor
キーワード
主題Scheme Other
主題 Hematopoietic Stem Cell Transplantation
キーワード
主題Scheme Other
主題 Leukapheresis
キーワード
主題Scheme Other
主題 小細胞肺癌
キーワード
主題Scheme Other
主題 高用量化学療法
キーワード
主題Scheme Other
主題 顆粒球コロニー刺激因子
キーワード
主題Scheme Other
主題 造血幹細胞移植
キーワード
主題Scheme Other
主題 幹細胞採取
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
その他のタイトル
その他のタイトル Phase I Dose Escalation Study of Multicyclic, Dose-Intensive Chemotherapy with Peripheral Blood Stem Cell Support for Small Cell Lung Cancer
著者 吉澤, 弘久

× 吉澤, 弘久

WEKO 94970

吉澤, 弘久

Search repository
松本, 尚也

× 松本, 尚也

WEKO 94971

松本, 尚也

Search repository
望月, 博史

× 望月, 博史

WEKO 94972

望月, 博史

Search repository
栗山, 英之

× 栗山, 英之

WEKO 94973

栗山, 英之

Search repository
各務, 博

× 各務, 博

WEKO 94974

各務, 博

Search repository
鈴木, 栄一

× 鈴木, 栄一

WEKO 94975

鈴木, 栄一

Search repository
下条, 文武

× 下条, 文武

WEKO 94976

下条, 文武

Search repository
著者別名
識別子 94977
識別子Scheme WEKO
姓名 Yoshizawa, Hirohisa
著者別名
識別子 94978
識別子Scheme WEKO
姓名 Matsumoto, Naoya
著者別名
識別子 94979
識別子Scheme WEKO
姓名 Mochizuki, Hiroshi
著者別名
識別子 94980
識別子Scheme WEKO
姓名 Kuriyama, Hideyuki
著者別名
識別子 94981
識別子Scheme WEKO
姓名 Kagamu, Hiroshi
著者別名
識別子 94982
識別子Scheme WEKO
姓名 Suzuki, Eiichi
著者別名
識別子 94983
識別子Scheme WEKO
姓名 Gejyo, Fumitake
抄録
内容記述タイプ Abstract
内容記述 A phase I dose-escalation study of multicyclic, ifosfamide, carboplatin, and etoposide (ICE) with sequential reinfusion of peripheral blood stem-cells (PBSCs) was conducted to determine the maximum-tolerated dose (MTD) of ICE. Twenty-seven patients with SCLC (LD : 9, ED : 18) were treated with ifosfamide (3000-9000mg/m^2, 24-hour-infusion), carboplatin (300-400mg/m^2), and etoposide (300mg/m^2) followed by subcutaneous injection of filgrastim (75μg/day) through day 4 to the day of PBSC collection. PBSC were harvested when the WBC count reached ≧5×10^9/L. The leukapheresis product was cryopreserved and reinfused on day 4 of the next cycle, which was started 48 hours after the last PBSC collection. The ifosfamide dose was escalated as follows : 3000mg/m^2 (level 1), 5000mg/m^2 (level 2), 7000mg/m^2 (level 3), 9000mg/m^2 (level 4). Patients with LD were treated with concurrent radiotherapy at 1.5 Gy twice daily for the initial 3 weeks to a total dose of 45Gy and MTD, defined separately. Patients were evaluated for hematologic and non-hematologic toxicity, actual dose intensities, as well as response to the therapy. The maximum-tolerated dose (MTD) was defined as the dose level at which the level produced more than 5 days of grade 4 myelosuppression or non-hematologic toxicity greater than grade 3 in two thirds of the patients. For ED cases, MTD was level 4 and the recommended dose of ifosfamide was 7000mg/m^2. For LD cases, the recommended dose of ifosfamide was 5000mg/m^2. The dose limiting toxicity of multicyclic ICE was hematologic toxicity and CNS toxicity which manifested as ataxia. Tumor responses were seen in all patients, with 14 patients showing a complete response. The actual total dose-intensity at the recommended dose level was 2.2 and 1.74, for ED and LD, respectively, compared with previously reported ICE regimens. PBSC support for dose-intensive ICE regimen permitted dose escalation of ifosfamide with a mean interval of 16-17 days. We conclude this regimen is well tolerated, with acceptable hematological and non-hematological toxicity.
書誌情報 新潟医学会雑誌
en : 新潟医学会雑誌

巻 115, 号 9, p. 432-437, 発行日 2001-09
出版者
出版者 新潟医学会
ISSN
収録物識別子タイプ ISSN
収録物識別子 00290440
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AN00182415
著者版フラグ
値 publisher
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 16:17:59.280079
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3